Witnessing the stock’s movement on the chart, on Wednesday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) set off with pace as it heaved 6.18% to $8.76, before settling in for the price of $8.25 at the close. Taking a more long-term approach, DAWN posted a 52-week range of $5.64-$13.53.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -38.09%. Meanwhile, its Annual Earning per share during the time was -38.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 1.35%. This publicly-traded company’s shares outstanding now amounts to $102.68 million, simultaneously with a float of $73.65 million. The organization now has a market capitalization sitting at $899.43 million. At the time of writing, stock’s 50-day Moving Average stood at $8.25, while the 200-day Moving Average is $7.38.
Day One Biopharmaceuticals Inc (DAWN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Day One Biopharmaceuticals Inc’s current insider ownership accounts for 28.27%, in contrast to 72.19% institutional ownership. According to the most recent insider trade that took place on Nov 17 ’25, this organization’s Gen Counsel & Secretary sold 4,319 shares at the rate of 8.91, making the entire transaction reach 38,503 in total value, affecting insider ownership by 62,626. Preceding that transaction, on Nov 17 ’25, Company’s COO and CFO sold 4,062 for 8.91, making the whole transaction’s value amount to 36,212. This particular insider is now the holder of 294,715 in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
Day One Biopharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 1.35% and is forecasted to reach -0.67 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 86.21% through the next 5 years, which can be compared against the -38.09% growth it accomplished over the previous five years trading on the market.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Let’s observe the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). It’s Quick Ratio in the last reported quarter now stands at 8.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.73.
In the same vein, DAWN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.49, a figure that is expected to reach -0.19 in the next quarter, and analysts are predicting that it will be -0.67 at the market close of one year from today.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Going through the that latest performance of [Day One Biopharmaceuticals Inc, DAWN]. Its last 5-days volume of 3.19 million indicated improvement to the volume of 1.61 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 47.88% While, its Average True Range was 55.98.
Raw Stochastic average of Day One Biopharmaceuticals Inc (DAWN) in the period of the previous 100 days is set at 59.35%, which indicates a major rise in contrast to 47.25% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.50 that was higher than 0.43 volatility it exhibited in the past 100-days period.
